• SyncroPatch 384/768PE

    APC with highest throughput on the market
  • SyncroPatch 384/768PE

    384 cells in parallel => upgradable to 768
  • SyncroPatch 384/768PE

    True HTS AND Gigaohm seals
  • SyncroPatch 384/768PE

    True internal perfusion with continuous data acquisition
  • SyncroPatch 384/768PE

    Assay flexibility via high tech

NaV1.8 - "Characterization of rNaV1.8 (ND7-23) on Nanion's SyncroPatch 96"

icon sp96   SyncroPatch 96 application note, (a predecessor model of the SyncroPatch 384PE)   logo pdf   (0.7 MB)
Cells were kindly provided by Millipore.

 

Summary:

The NaV1.8 gene (originally named PN3 or SNS; gene symbol SCN10A) encodes a voltage-gated sodium (NaV) channel, selectively expressed in dorsal root ganglion (DRG) neurons. DRGs transmit peripheral stimuli to the central nervous system and are involved in nociception. Different NaV channels play a key role in modulation of DRG action potentials. In particular, the fast upstroke of the action potential is mediated by NaV channels. NaV channels are in part characterized by their TTX-sensitivity (TTX-resistant [TTXr], TTX-sensitive [TTXs]). NaV1.8 is a TTXr channel. Compared with other NaV channels, NaV1.8 has slow activation and inactivation kinetics and is opened at relatively high voltages. It is an interesting drug target for inflammatory and neuropathic pain, because modulation of NaV1.8 by inflammatory mediators seems to be a key mechanism of DRG nociceptor sensitization and activation. Interestingly, NaV1.8 has been reported to play an important role in the perception of cold pain. In this Application Note we present data from 1 exemplary run (96-well plate) on the SyncroPatch 96 characterizing ND7-23 cells (a rat DRG/mouse neuroblastoma hybrid) stably transfected with rat NaV1.8. All experiments were performed in the presence of 100 nM TTX to block the endogenous TTXs Na+ current present in these cells. The NaV1.8 activation and inactivation properties, tetracaine and lidocaine sensitivities recorded on the SyncroPatch 96 were consistent with those reported in the literature.

Back to Overview

Contact Us

Please type your full name.
Invalid email address.
Invalid Input
Invalid Input
Nanion Technologies GmbH

Ganghoferstr. 70A
D-80339 Munich - Germany
info@nanion.de